Conditional transgenic mouse models: From the basics to genome-wide sets of knockouts and current studies of tissue regeneration

Regenerative Medicine

Volumn 3, Issue 2, 2008, Pages 217-235

  Bockamp, Ernesto ^a   Sprengel, Rolf ^b   Eshkind, Leonid ^a   Lehmann, Thomas ^c   Braun, Jan M ^c   Emmrich, Frank ^c   Hengstler, Jan G ^d  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE FOR MEDICAL RESEARCH   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d TU DORTMUND UNIVERSITY   (Germany)

Author keywords

catenin; c Met; Conditional expression systems; Gene targeting; Gene trapping; Knockout mice; Transgenic mice

Indexed keywords

ADENOVIRUS VECTOR; CRE RECOMBINASE; DNA; DOXYCYCLINE; ESTROGEN RECEPTOR; HYBRID PROTEIN; MICRORNA; RECOMBINASE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STEROID RECEPTOR; TAMOXIFEN; TETRACYCLINE; TRANSACTIVATOR PROTEIN; TRANSFER RNA;

ANIMAL MODEL; CELL TYPE; CHROMOSOME INSERTION; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION; DEGENERATIVE DISEASE; DNA BINDING; DOWN REGULATION; EMBRYONIC STEM CELL; ENZYME MODIFICATION; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENE INDUCTION; GENE MUTATION; GENE TARGETING; GENE TECHNOLOGY; GENETIC TRANSCRIPTION; GENOME; HETEROZYGOSITY; HOMOLOGOUS RECOMBINATION; HOMOZYGOSITY; HUMAN; INTRON; LIVER REGENERATION; MOUSE; MOUSE STRAIN; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; TISSUE REGENERATION; TRANSGENIC MOUSE; TRANSGENICS; WOUND HEALING;

ANIMALS; GENOME; MICE; MICE, TRANSGENIC; REGENERATION;

EID: 42249099328     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460751.3.2.217     Document Type: Review

References (149)

1. Bockamp E, Maringer M, Spangenberg C et al.: Of mice and models: improved animal model for biomedical research. Physiol, Genomics 11, 115-132 (2002).
2. Glaser S, Anastassiadis K, Stewart AF: Current issues in mouse genome engineering. Nat. Genet. 37, 1187-1193 (2005).
3. Nagy A, Gertsenstein M, Vintersten R, Behringer M: Manipulating the Mouse Embryo - A Laboratory Manual (Third Edition). Cold Spring Harbor Press, NY, USA (2002).
4. Prawitt D, Brixel L, Spangenberg C et al.: RNAi knock-down mice: an emerging technology for post-genomic functional genetics. Cytogenet. Genome Res. 105, 412-421 (2004).
5. Ristevski S: Making better transgenic models: conditional, temporal, and spatial approaches. Mol. Biotechnol. 29, 53-163 (2005).
6. Sung YH, Song J, Lee HW: Functional genomics approach using mice. J. Biochem. Mol. Biol. 37, 122-132 (2004).
7. Gordon JW, Scangos GA, Plotkin DJ, Barbosa JA, Ruddle FH: Genetic transformation of mouse embryos by microinjection of purified DNA. Proc. Natl Acad. Sci. USA 77, 7380-7384 (1980).
8. Rulicke T: Pronuclear microinjection of mouse zygotes. Methods Mol. Biol.. 254, 165-194 (2004).
9. Efrat S, Leiser M, Wu YJ et al.: Rjbozyme-mediated attenuation of pancreatic β-cell glucokinase expression in transgenic mice results in impaired glucose-induced insulin secretion. Proc. Natl Acad. Sci. USA 91, 2051-2055 (1994).
10. Erickson RP: Antisense transgenics in animals. Methods 18, 304-310- (1999).
11. Kashani-Sabet M, Liu Y, Fong S et al.: Identification of gene function and functional pathways by systemic plasmid-based ribozyme targeting in adult mice. Proc. Natl Acad. Sci. USA 99, 3878-3883 (2002).
12. Larsson S, Hotchkiss G, Andang M et al.: Reduced β 2-microglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme. Nucleic Acids Res. 22, 2242-2248 (1994).
13. Stegmeier F, Hu G, Ricides RJ, Hannon GJ, Elledge SJ: A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA, interference in mammallan cells. Proc. Natl Acad. Sci. USA 102, 13212-13217(2005).
14. Szulc J, Wiznerowicz M, Sauvain MO, Trono D, Aebischer P: A versatile tool for conditional gene expression and knockdown. Nat. Methods 3, 109-116 (2006).
15. Ventura A, Meissner A, Dillon CP et al.: Cre-lox-regulated conditional RNA interference from transgenes. Proc. Natl Acad. Sci. USA 101, 10380-10385 (2004).
16. Navas PA, Swank RA, Yu M, Peterson KR, Stamatoyannopoulos G: Mutation of a transcriptional motif of a distant regulatory element reduces the expression of embryonic and fetal globin genes. Hum. Mol, Genet. 12, 2941-2948 (2003).
17. Sanchez MJ, Bockamp EO, Miller J, Gambardella L, Green AR: Selective rescue of early haematopoletic progenitors in Scl(-/-) mice by expressing Scl under the control of a stem cell enhancer. Development 128, 4815-4827 (2001).
18. Sinclair AM, Gottgens B, Barton LM et al.: Distinct 5′ SCL enhancers direct transcription to developing brain, spinal cord, and endothelium: neural expression is mediated by GATA factor binding sites. Dev. Biol. 209, 128-142 (1999).
19. Wilson C, Betlen HJ, Gehring WJ: Position effects on eukaryotic gene expression. Annu. Rev. Cell Biol. 6, 679-714 (1990).
20. Bronson SK, Plaehn EG, Kluckman KD, Hagaman JR, Maeda N, Smithies O: Single-copy transgenic mice with chosen-site integration. Proc. Natl Acad. Sci. USA 93, 9067-9072 (1996).
21. Giraldo P, Rival-Gervier S, Houdebine LM, Montoliu L: The potential benefits of insulators on heterologous constructs in transgenic animals. Transgenic Res. 12, 751-755 (2003).
22. Giraldo, P, Montoliu L: Size matters: use of YACs, BACs and PACs in transgenic animals. Transgenic Res. 10, 83-103 (2001).
23. Sparwasser T, Gong S, Li JY, Eberl G: General method for the modification of different BAC types and the rapid generation of BAC transgenic mice. Genesis 38, 39-50 (2004)
24. Gong S, Yang XW, Li C, Heintz N: Highly efficient modification of bacterial artificial chromosomes (BACs) using novel shuttle vectors containing the R6kγ origin of replication. Genome Res. 12, 1992-1998 (2002).
25. Lee EC, Yu D, Martinez de Velasco J et al.: A highly efficient Esherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. Genomics 73, 56-65 (2001).
26. Wang J, Sarov M, Rientjes J et al.: An improved recombineering approach by adding RecA to lambda red recombination. Mol. Biotechnol. 32, 43-53 (2006).
27. Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG: Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res. 33, e36 (2005).
28. Rijkers T, Peetz A, Ruther U: Insertional mutagenesis in transgenic mice. Transgenic Res. 3, 203-215 (1994).
29. Ikawa M, Tanaka N, Kao WW-Y, Verma IM: Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy. Mol. Ther. 8, 666-673 (2003).
30. Tiscornia G, Singer O, Ikawa M, Verma IM: A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc. Natl Acad. Sci. USA 100, 1844-1848 (2003).
31. Evans MJ, Kaufman MH: Establishment in culture of pluripotential cells from mouse embryos. Nature 292, 154-156 (1981).
32. Martin GR: Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc. Natl Acad. Sci. USA 78, 7634-7638 (1981).
33. Smithies O, Gregg RG, Boggs SS, Koralewski MA, Kucherlapati RS: Insertion or DNA sequences into the human chromosomal β-globin locus by homologous recombination. Nature 317, 230-234 (1985).
34. Thomas KR, Capecchi MR: Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 51, 503-512 (1987).
35. Borrelli E, Heyman R, Hsi M, Evans RM: Targeting of an inducible toxic phenotype in animal cells. Proc. Natl Acad. Sci. USA 85, 7572-7576 (1988).
36. Chen YT, Bradley A: A new positive/negative selectable marker, puDeltatk, for use in embryonic stem cells. Genesis 28, 31-35 (2000)
37. Yanagawa Y, Kobayashi T, Ohnishi M et al.: Enrichment and efficient screening of ESCs containing a targeted mutation: the use of DT-A gene with the polyadenylation signal as a negative selection maker. Transgenic Res. 8, 215-221 (1999).
38. Collins FS, Rossant J, Wurst W: A mouse for all reasons. Cell 128, 9-13 (2007).
39. Collins FS, Finnell RH, Rossant J, Wurst W: A new partner for the International Knockout Mouse Consortium. Cell 129, 235 (2007).
40. Nord AS, Chang PJ, Conklin BR et al.: The International Gene Trap Consortium Website: a portal to all publicly available gene trap cell lines in mouse. Nucleic Acids Res. 34, D642-D648 (2006).
41. Phillips TJ, Hen R, Crabbe JC: Complications associated with genetic background effects in research using knockout mice. Psychopharmacology (Berl.) 147, 5-7 (1999).
42. Sanford LP, Kallapur S, Ormsby I, Doetschman T: Influence of genetic background-on knockout mouse phenotypes. Methods Mol. Biol. 158, 217-225 (2001).
43. Bowers BJ, Owen EH, Collins AC, Abellovich A, Tonegawa S, Wehner JM: Decreased ethanol sensitivity and tolerance development in γ-protein kinase C null mutant mice is dependent on genetic background. Alcohol. Clin. Exp. Res. 23, 387-397 (1999).
44. Sigmund CD: Viewpoint: are studies in genetically altered mice out of control? Arterioscler. Thromb. Vasc. Biol. 20, 1425-1429 (2000).
45. Enomoto A, Itoh K, Nagayoshi E et al.: High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol. Sci. 59, 169-177 (2001).
46. Pennacchio, LA, Olivier M, Hubacek JA et al.: An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294, 169-173 (2001).
47. Janson J, Soeller WC, Roche PC et al.: Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc. Natl Acad. Sci. USA 93, 7283-7288 (1996).
48. Garcia-Otin AL, Guillou F: Mammalian genome targeting using site-specific recombinases. Front. Biosci. 11, 1108-1136 (2006).
49. Mallo M: Controlled gene activation and inactivation in the mouse. Front. Biosci. 11, 313-327 (2006).
50. Schiffer, IB, Gebhard S, Heimerdinger CK et al.: Switching off her-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission. Cancer Res. 63, 7221-7231 (2003).
51. Trost TM, Lausch EU, Fees SA et al.: Premature senescence is a primary fail-safe mechanism of ERBB2-driven tumorigenesis in breast carcinoma cells. Cancer Res. 65, 840-849 (2005).
52. Spangenberg C, Lausch EU, Trost TM et al.: ERBB2-mediated transcriptional up-regulation of the α5β1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions. Cancer Res. 66, 3715-3725 (2006).
53. Hausherr CK, Schiffer IB, Gebhard S et al.: Dephosphorylation of p-ERK1/2 in relation to tumor remission after HER-2 and Raf1 blocking therapy in a conditional mouse tumor model. Mol. Carcinog. 45, 302-308 (2006).
54. Henstler JG, Bockamp EO, Hermes M et al.: Oncogene-blocking therapies: new insights from conditional mouse tumor models. Curr. Cancer Drug Targets 6, 603-612 (2006).
55. Pao W, Klimstra DS, Fisher GH, Varmus HE: Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumor maintenance. Proc. Natl Acad. Sci. USA 100, 8764-8769 (2003).
56. Gossen M, Bujard H: Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl Acad. Sci. USA 89, 5547-5551 (1992).
57. Baron U, Freundlieb S, Gossen M, Bujard H: Co-regulation of two gene activities by tetracycline via a bidirectional promoter. Nucleic Acids Res. 23, 3605-3606 (1995).
58. Eger K, Hermes M, Uhlemann K et al.: 4-epidoxycycline: an alternative to doxycycline to control gene expression in conditional mouse models. Biochem. Biophys. Res. Commun. 323, 979-986 (2004).
59. Furth PA, St Onge L, Boger H et al.: Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc. Natl Acad. Sci. USA 91, 9302-9306 (1994).
60. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H: Transcriptional activation by tetracyclines in mammalian cells. Science 268, 1766-1769 (1995).
61. Hasan MT, Schonig K, Berger S, Graewe W, Bujard H: Long-term, noninvasive imaging of regulated gene expression in living mice. Genesis 29, 116-122 (2001).
62. Kistner A, Gossen M, Zimmermann F et al.: Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc. Natl Acad. Sci. USA 93, 10933-10938 (1996).
63. Freundlieb S, Schirra-Muller C, Bujard H: A tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells. J. Gene Med. 1, 4-12 (1999).
64. Zhu Z, Ma B, Homer RJ, Zheng T, Elias JA: Use of the tetracycline-controlled transcriptional silencer (tTS) to eliminate transgene leak in inducible overexpression transgenic mice. J. Biol. Chem. 276, 25222-25229 (2001).
65. Forster K, Helbi V, Lederer T, Urlinger S, Wittenburg N, Hillen W: Tetracycline-Inducible expression systems with reduced basal activity in marnmallan cells. Nucleic Acids Res. 27, 708-710 (1999).
66. Hayakawa T, Yusa K, Kouno M, Takeda J, Horie K: Bloom's syndrome gene-deficient phenotype in mouse primary cells induced by a modified tetracycline-controlled transsilencer. Gene 369, 80-89 (2006).
67. Uchida S, Sakai S, Furuichi T et al.: Tight regulation of transgene expression by tetracycline-dependent activator and repressor in brain. Genes Brain Behav. 5, 96-106 (2006).
68. Krueger C. Danke C, Pflelderer K et al.: A gene regúlation system with four district expression levels. J Gene Med. 8, 1037-1047 (2006)
69. Pluta K, Luce MJ, Bao L, Agha-Mohammadi S, Reiser J: Tight control of transgene expression by lentivirus vectors containing, second-generation tetracycline-responsive promoters. J. Gene Med. 7, 803-817 (2005).
70. Izumi M, Gilbert DM: Homogeneous tetracycline-regulatable gene expression in mammalian fibroblasts. J Cell. Biochem. 76, 280-289 (1999).
71. Akagi K, Kanai M, Saya H, Kozu T, Berns A: A novel tetracycline-dependept transactivator with E2F4 transcriptional activation domain. Nucliec Acids Res. 29, E23 (2001).
72. Baron U, Gossen M, Bujard H: Tetracycline-controlled transcription in eukaryotes: novel transactivators with graded transactivation potential. Nucleic Acids Res. 23, 2723-2729 (1997).
73. Urlinger S, Helbi V, Guthmann J, Pook E, Grimm S, Hillen W: The p65 domain from NF-κB is an efficient human activator in the tetracycline-regulatable gehe expression system. Gene 247, 103-110 (2000).
74. Krueger C, Berens C, Schimidt A, Schnappinger D, Hillen W: Single-cham Tet transregulators. Nucleic Acids Re. 31, 3050-3056 (2003).
75. Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W: Exploring the sequence space for tetracycline-dependent transcriptional activitors: novel mutations yield expanded range and sensitivity. Proc. Natl Acad. Sci. USA 97, 7963-7968 (2000).
76. Lakso M, Sauer B, Mosinger B Jr. et al.: Targeted oncogene activation by site-specific recombination in transgenic mice. Proc. Natl Acad. Sci. USA 89, 6232-6236 (1992).
77. Orban PC. Chul D, Marth JD: Tissue- and site-specific DNA recombination in transgenic mice. Proc. Natl Acad. Sci. USA 89, 6861-6865 (1992).
78. Hamilton DL, Abremski K: Site-specific recombination by the bacteriophage P1 lox-Cre system. Cre-mediated synapsis of two lox sites. J. Mol. Biol. 178, 481-486 (1984).
79. Branda CS, Dymecki SM: Talking about a revolution: The impact of site-specific recombinases on genetic analyses in mice. Dev Cell 6, 7-28 (2004).
80. Van der Weyden L, Adams DJ, Bradley A: Tools for targeted manipulation of the mouse genome. Physiol. Genomics 11. 133-164 (2002).
81. Rodriguez CI, Buchholz F, Galloway J et al.: High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. Nat. Genet. 25, 139-140 (2000).
82. Schonig K, Schwenk F, Rajewsky K, Bujard H: Stringent doxycycline dependent control of CRE recombinase in vivo. Nudeir Acids Res. 30, e134 (2002).
83. Shimshek DR, Jensen V, Celikei T et al.: Forebrain-specific glutamate receptor B deletion impairs spatial memory but not hippocampal field long-term potentiation. J. Neurosci. 26, 8428-8440 (2006).
84. Brocard J,Warot X, Wendling O et al.: Spatio-temporally controlled site-specific somatic mutagenesis in th~e mouse. Proc. Natl Acad. Sci. USA 94, 14559-14563 (1997).
85. Buchholz F, Stewart AF: Alteration of Cre recombinase site specificity by substrate-linked protein evolution. Nat. Biotechnol. 19, 1047-1052 (2001).
86. Koresawa Y, Miyagawa S, Ikawa M et al.: A new Cre recombinase gene based on optimal codon usage in mammals: a powerful material for organ-specific gene targeting. Transplant. Proc. 32, 2516-2517 (2000).
87. Santoro SW, Schultz PG: Directed evolution of the site specificity of Cre recombinase. Proc. Natl Acad. Sci. USA 99, 4185-4190 (2002).
88. Shimshek DR, Kim J, Hubner MR et al.: Codon-improved Cre recombinase (iCre) expression in the mouse. Genesis 32, 19-26 (2002).
89. Vooijs M, Jonkers J, Berns A: A highly efficient ligand-regulated Cre recombinase mouse line shows that LoxP recombination is position dependent. EMBO Rep. 2, 292-297 (2001).
90. Friedel RH, Seisenberger C, Kaioff C et al.: EUCOMM the European Conditional Mouse Mutagenests Program. Brief. Funct. Genom. Proteom. 6, 180-185 (2007).
91. Schnütgen F, De-Zolt S, Van Sloun P et al.: Genomewide production of multipurpose alleles for the functional analysis of the mouse genome. Proc. Natl Acad. Sci. USA 102, 7221-7226 (2005).
92. Meister G, Tuschl T: Mechanisms of gene silencing by double-stranded RNA. Nature 431, 343-349 (2004).
93. Tomari Y, Zamore PD: Perspective: machines for RNAi. Genes Dev. 19, 517-529 (2005).
94. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498 (2001).
95. Hasuwa, H, Kaseda K, Einarsdottir T, Okabe M: Small interfering RNA and gene silencing in transgenic mice and rats. FEBS Lett. 532, 227-230 (2002).
96. Coumoul X, Deng CX: RNAi in mice: a promising approach to decipher gene functions in vivo. Biochimie 88, 637-643 (2006).
97. Lu PY, Me F, Woodle MC: In vivo application of RNA interference: from functional genomics to therapeutics. Adv. Genet. 54, 117-142 (2005).
98. Sandy P, Ventura A, Jacks T: Mammalian RNAi: a practical guide. Biotechniques 39, 215-224 (2005).
99. Wiznerowicz M, Szulc J, Trono D: Tuning silence: conditional systems for RNA interference. Nat. Methods 3, 682-688 (2006).
100. Hemann MT, Fridman JS, Zilfou JT et al.: An epi-allelic series of p53 hypmorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat. Genet. 33, 396-400 (2003).
101. Rosenbauer F, Wagner K, Kutok JL et al.: Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat. Genet. 36, 624-630 (2004).
102. Jackson AL, Bartz SR, Schelter J et al.: Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21, 635-637 (2003).
103. Huppi K, Martin SE, Caplen NJ: Defining and assaying RNAi in manunalian cells. Mol. Cell 17, 1-10 (2005).
104. Grimm D, Streetz KL, Jopling CL et al.: Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537-541 (2006).
105. Hommel JD, Sears RM, Georgescu D, Simmons DL, DiLeone RJ: Local gene knockdown in the brain using viral-mediated RNA interference. Nat. Med. 9, 1539-1544 (2003).
106. Kishida T, Asada H, Gojo S et al.: Sequence-specific gene silencing in murine muscle induced by electroporation-mediated transfer of short interfering RNA. J. Gene Med. 6. 105-110 (2004).
107. Matsuda T, Cepko CL: Electroporation and RNA interference in the rodent retina in vivo and in vitro Proc. Natl Acad. Sci. USA 101, 16-22 (2004).
108. McCaffrey AP, Nakal H, Pandey K et al.: Inhibition of hepatitis B virus in mice by RNA interference. Nat. Biotechnol. 21, 639-644 (2003).
109. Song E, Lee SK, Wang et al.: RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9, 347-351 (2003).
110. Soutschek J, Akinc A, Bramlage B et al.: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178 (2004).
111. Xia H, Mao Q, Paulson HL, Davidson BL: siRNA-mediated gene silencing in vitro and in vivo.. Nat Biotechnol. 20, 1006-1010 (2002).
112. De Fougerolles A, Manoharan M, Meyers R, Vornlocher HP: RNA interference in vivo. toward synthetic small inhibitory. RNA-based therapeutics. Method Enzymol. 392, 278-296 (2005).
113. Leonard JN, Schaffer DV: Antiviral RNAi therapy: emerging approaches for hitting a moving target. Gene Ther. 13, 532-540 (2006).
114. Kunath T, Gish G, Lickert H, Jones N, Pawson T, Rossant J: Transgenic RNA interference in ESC-derived embryos recapitulates a genetic null phenotype. Nat. Biotechnol. 21, 559-561 (2003).
115. Rubinson DA, Dillon CP, Kwiatkowski AV et al.: A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat. Genet. 33, 401-406 (2003).
116. Chang HS, Lin CH, Chen YC, Yu WC: Using siRNA technique to generate transgenic animals with spatiotemporal and conditional gene knockdown. Am. J. Pathol. 165, 1535-1544 (2004).
117. Coumoul X, Shukla V, Li C, Wang RH, Deng CX: Conditional knockdown of Fgfr2 in mice using Cre-LoxP induced RNA interference. Nucleic Acid Res. 33, e102 (2005).
118. Xia XG, Zhou H, Samper E, Melov S, Xu Z: Pol II-expressed shRNA knocks down Sod2 gene-expression and causes phenotypes of the gene knockout in mice. PLoS Genet. 2, e10 (2006).
119. Dickins RA, Hemann MT, Zilfou JT et al.: Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet. 37, 1289-1295 (2005).
120. Moffat J, Grueneberg DA, Yang X et al.: A lentiviral RNA1 library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124, 1283-1298 (2006).
121. Silva JM, Li MZ, Chang K et al.: Second-generation shRNA libraries covering the mouse and human genomes. Nat. Genet. 37, 1281-1288 (2005).
122. Cao W, Hunter R, Strnatka D, McQueen CA, Erickson RP: DNA constructs designed to produce short hairpin, interfering RNAs in transgenic mice sometimes show early lethality and an interferon response. J Appl. Genet. 46, 217-225 (2005).
123. Buch T, Heppner FL, Tertilt C et al.: A Cre-inducible diphtheria toxin receptor mediatESC lineage ablation after toxin administration. Nat. Methods 2, 419-426 (2005).
124. Bennett CL, Clausen BE: DC ablation In mice: promises, pitfalls, and challenges. Trends Immunol. 28, 519-525 (2007).
125. Tatsumi S, Ishii K, Amizuka N et al.: Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab. 5, 464-475 (2007).
126. Carlotti F, Zaldumbide A, Martin P, Boulukos KE, Hoeben RC, Pognonec P: Development of an inducible suicide gene system based on human caspase 8. Cancer Gene Ther. 12, 627-639 (2005).
127. Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai L-H: Recovery of learning and memory is associated with chromatin remodelling. Nature 447, 178-182 (2007).
128. Sweatt JD: Down memory lane. Nature 447, 151-152 (2007).
129. Tremblay P, Bouzamondo-Bernstein E, Heinrich C, Prusiner SB, DeArmond SJ: Developmental expression of PrP in the post-implantation embryo. Brain Res. 1139, 60-67 (2007).
130. Tremblay P, Meiner Z, Galou M et al.: Doxycycline control of prion protein transgene expression modulates prion disease in mice. Proc. Natl Acad Sci. USA 95, 12580-12585 (1998).
131. Safar JG, DeArmond SJ, Kociuba K et al.: Prion clearance in bigenic mice. J. Gen. Virol. 86, 2913-2923 (2005).
132. Tanaka Y, Igarashi S, Nakamura M et al.: Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin. Neurobiol. Dis. 21, 381-391 (2006).
133. Michalopoulos GK, DeFrances M: Liver regeneration. Adv Biochem. Eng. Biotechnol. 93, 101-134 (2005).
134. Hengstler JG, Utesch D, Steinberg P et al.: Cryopreserved primary hepatocytes as an in vitro model for the evaluation of drug metabolism and enzyme induction. Drug Metab. Rev. 32. 81-118 (2000).
135. Hengstler JG, Brulport M, Schormann W et al.: Generation of human hepatocytes by stem cell technology: definition of the hepatocyte. Expert Opin. Drug Metab. Toxicol. 1, 61-74 (2006).
136. Nussler A, Konig S, Ott M et al.: Present status and perspectives of cell-based therapies for liver diseases. J. Hepatol. 45, 144-159 (2006).
137. Von Mach MA, Hengstler JG, Brulport M et al.: In vitro cultured islet-derived progenitor cells of human origin express human albumin in severe combined immunodeficiency mouse liver in vivo. Stem Cells 22, 1134-1141 (2004).
138. Ruhnke M, Ungefroren H, Nussler A et al.: Reprogramming of human peripheral blood monocytes into functional hepatocyte and pancreatic islet-like cells. Gastroenterology 128, 1774-1186 (2005).
139. Beerheide W, von Mach MA, Ringel M et al.: Downregulation of β2-microglobulin in human cord blood somatic stem cells after transplantation into livers of SCID-mice: an escape mechanism of stem cells? Biochem. Biophys. Res. Commun. 294, 1052-1063 (2002).
140. Phaneuf D, Moscioni AD, LeClair C, Raper SE, Wilson JM: Generation of a mouse expressing a conditional knockout of the hepatocyte growth factor gene demonstration of impaired liver regeneration. DNA Cell Biol. 23, 592-603 (2004).
141. Paranjpe S, Bowen WC, Bell AW, Nejak-Bowen K, Luo JH, Michalopoulos GK: Cell cycle effects resulting from inhibition of hepatocyte growth factor and its receptor c-Met in regenerating rat livers by RNA interference. Hepatology (2008) (Epub ahead of print).
142. Tan X, Behari J, Cieply B, Michalopoulos GK, Monga SP: Conditional deletion of β-catenin reveals its role in liver growth and regeneration. Gastroenterology 131, 1561-1572 (2006).
143. Li F, Xiang Y, Potter J, Dinavahi R, Dang CV, Lee LA: Conditional deletion of c-myc dose not impair liver regeneration. Cancer Res. 66, 5608-5612 (2006).
144. Croquelois A, Blindenbacher A,Terracciano L et al.: Inducible inactivation of Notch1 causes nodular regenerative hyperplasia in mice. Hepatology 41, 487-496 (2005).
145. Malone D, Di Carlo E, Li W et al.: Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J. 17 5588-5597 (1998).
146. Chmielowiec J, Borowiak M, Morkel M et al.: c-Met is essential for wound healing in the skin. J Cell Biol. 177, 151-162 (2007).
147. Cheoa SS, Wei Q, Gurung A et al.: β-catenin regulates wound size and mediates the effect of TGF-β in cutaneous healing. FASEB J. 20, 692-701 (2006).
148. Giuriato S, Rabin K, Fan AC, Shachaf CM, Feisher DW. Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer. Semin. Cancer Biol. 14, 3-11 (2004).
149. Jonkers J, Berns A: Conditional mouse models of sporadic cancer. Nat. Rev. Cancer 2, 251-265 (2002).